Johnson & Johnson's Spravato Sales Growth Supports Psychedelic Drug Opportunity: Jefferies

Jefferies analysts noted that Johnson & Johnson's (NYSE:JNJ) stronger-than-expected second-quarter sales of its depression drug Spravato could signal a positive read-through for psychedelic drug developers such as Atai Life Sciences (NASDAQ:ATAI), Compass Pathways (NASDAQ:CMPS), and Cybin (NYSE-A:CYBN).

Rating Change

Jefferies did not change its rating on any of these stocks but highlighted that Spravato's strong sales growth supports the market opportunity for psychedelic drugs.

Analyst Rationale

The analysts believe that the commercial success of Spravato, an FDA-approved treatment for treatment-resistant depression, validates the therapeutic potential and commercial viability of psychedelic-based therapies. This could reduce regulatory and market risks for companies like Atai, Compass, and Cybin, which are developing similar treatments.

Context

Johnson & Johnson is a well-established pharmaceutical company, and Spravato's success provides confidence in the psychedelic drug class. However, the smaller companies are still in early stages and face significant regulatory and commercial hurdles.

What to Make of It

While Spravato's sales are a positive indicator, investors should consider each company's individual risks, including development stage, regulatory path, and competitive landscape.